← All drugs
Drug · FAERS side-effect profile with label screen

Aspirin 325Mg side effects: what 710 FDA adverse event reports show

Aspirin 325Mg · 9 reaction terms · 58 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Nonsteroidal Anti-inflammatory Drug, Platelet Aggregation Inhibitor

FDA label (Established Pharmacologic Class) · compare the class

Who reports

710 reports · 73% serious · 73 with death outcome · 48% female

openFDA FAERS counts, all years, deduplication not applied

Used for

temporarily relieves minor aches and pains due to: headache muscle pain toothache menstrual pain colds minor pains of arthritis temporarily reduces fever

FDA label, Indications and Usage

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 4 strongest signals

Reporting / coding artifact 1Not in label — unassessed 3
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 5 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Hospice care927.0
14.1–51.7ROR 27.3 · χ² 200 / p 1e-45
25.4 EB05 13.9 · IC025 +2.4
3/3 methods agree
Not in label — unassessedserious PRR 27.5no trial data cached
Subdural haematoma714.4
6.9–30.1ROR 14.5 · χ² 74 / p 3e-18
11.4 EB05 4.8 · IC025 +1.6
3/3 methods agree
Not in label — unassessedserious PRR 11.4no trial data cached
Product substitution issue199.8
6.3–15.2ROR 10.0 · χ² 141 / p 8e-33
8.7 EB05 5.6 · IC025 +2.2
3/3 methods agree
Reporting / coding artifactserious PRR 13.8no trial data cached
Diabetic ketoacidosis67.4
3.3–16.4ROR 7.4 · χ² 27 / p 1e-7
5.1 EB05 2.5 · IC025 +0.9
3/3 methods agree
Not in label — unassessedserious PRR 5.9no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Product substitution issue199.8
6.3–15.2ROR 10.0 · χ² 141 / p 8e-33
8.7 EB05 5.6 · IC025 +2.2
3/3 methods agree
Reporting / coding artifactserious PRR 13.8no trial data cached
Hospice care927.0
14.1–51.7ROR 27.3 · χ² 200 / p 1e-45
25.4 EB05 13.9 · IC025 +2.4
3/3 methods agree
Not in label — unassessedserious PRR 27.5no trial data cached
Subdural haematoma714.4
6.9–30.1ROR 14.5 · χ² 74 / p 3e-18
11.4 EB05 4.8 · IC025 +1.6
3/3 methods agree
Not in label — unassessedserious PRR 11.4no trial data cached
Diabetic ketoacidosis67.4
3.3–16.4ROR 7.4 · χ² 27 / p 1e-7
5.1 EB05 2.5 · IC025 +0.9
3/3 methods agree
Not in label — unassessedserious PRR 5.9no trial data cached
Subarachnoid haemorrhage411.6
4.4–30.7ROR 11.6 · χ² 29 / p 4e-8
6.8 EB05 2.5 · IC025 +0.6
3/3 methods agree
Not in label — unassessedserious PRR 9.2no trial data cached
Therapy change412.3
4.6–32.6ROR 12.3 · χ² 31 / p 1e-8
7.2 EB05 2.6 · IC025 +0.7
3/3 methods agree
Reporting / coding artifactserious n=1no trial data cached
Incorrect dose administered by device33.5
1.1–10.8ROR 3.5 · χ² 3 / p 0.038
2.6 EB05 1.0 · IC025 -0.7
PRR-only: not supported by EBGM or IC
Reporting / coding artifactserious n=1no trial data cached
Tendon rupture (torn tendon)37.2
2.3–22.1ROR 7.2 · χ² 10 / p 7e-4
4.0 EB05 1.5 · IC025 -0.1
PRR-only: not supported by EBGM or IC
Not in label — unassessedserious PRR 6.2no trial data cached
Gastric haemorrhage37.6
2.5–23.7ROR 7.7 · χ² 11 / p 4e-4
4.2 EB05 1.6 · IC025 -0.1
PRR-only: not supported by EBGM or IC
Not in label — unassessedserious PRR 6.3no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Aspirin 325Mg?

In FDA FAERS, the most frequently co-reported reaction terms for Aspirin 325Mg are hospice care, subdural haematoma, diabetic ketoacidosis, subarachnoid haemorrhage, tendon rupture, gastric haemorrhage. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Aspirin 325Mg have an FDA boxed warning?

No. The FDA label retrieved for Aspirin 325Mg has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Aspirin 325Mg causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.